NCT05004441已完成2 期
Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer：HCCSC C02 Trial
Zhou Fuxiang2 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2021年7月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 2
- 主要终点
- objective response rate (ORR)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of Fruquintinib Combined With mFOLFOX6/FOLFIRI as the first-line treatment of Metastatic Colorectal Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years, ≤75 years
- •Histologically confirmed unresectable or metastatic stage colorectal cancer
- •Known RAS activating mutation/wild type and BRAF wild type;
- •Patients have not received systematic treatment for unresectable or metastatic colorectal cancer (those who have received adjuvant or neoadjuvant chemotherapy with one regimen and relapsed more than 12 months after the end of chemotherapy can be enrolled);
- •At least one measurable disease according to RECIST 1.1 guidelines for solid tumors；
- •Life expectancy > 12 weeks
- •Patients must have adequate organ function
- •Women of childbearing age must have a negative pregnancy test within the first day of the study, and contraceptive methods should be taken during the study until 6 months after the last administration;
- •Informed consent has been signed.
排除标准
- •Have received other systemic anti-tumor therapies within 2 weeks before recruited(eg.chemotherapy or radiotherapy, immunotherapy, biological or hormonal therapy, or any VEGFR inhibitor treatment);
- •Known BRAF activating mutation
- •systolic blood pressure > 140mmHg or diastolic blood pressure > 90mmHg regardless of any antihypertensive drugs; Or patients need more than two antihypertensive drugs;
- •Clinically significant electrolyte abnormality;
- •Proteinuria ≥ 2+ (1.0g/24hr);
- •Patients have untreated central nervous system metastasis;
- •Patients have not recovered from all toxicities associated with prior anti-tumor therapy ,to acceptable baseline status, or a National Cancer Institute Common Terminology Criteria for Adverse Events(NCI CTCAE v5.0) Grade of 0 or 1, except for alopecia and oxaliplatin induced neurotoxicity ≤ 2 , and the previous surgery did not recover completely;
- •Have received other systemic anti-tumor therapies within 4 weeks before recruited;
- •Clinical uncontrolled active infections, such as acute pneumonia and active hepatitis B / C (previous history of hepatitis B virus infection, whether drug controlled or not, HBV DNA ≥ 104) × Copy number or ≥ 2000 IU / ml);
- •Dysphagia or known malabsorption of drugs;
- •Active gastric and duodenal ulcer, ulcerative colitis or uncontrolled hemorrhage in GI;
- •Have evidence or history of bleeding tendency within 2 months after enrollment, the researcher assessed that moderate or severe bleeding tendency was not suitable for enrollment;
- •Stroke (including transient ischemic attack) occurred within 12 months before admission;
- •Patients had other malignant tumors in the past 5 years or at the same time (except for the cured skin basal cell carcinoma and cervical carcinoma in situ);
- •Pregnant or lactating women;
- •Allergic to fruquintinib；
- •History of immunodeficiency, including HIV positive, other acquired or congenital immunodeficiency diseases, or organ transplantation;
- •Patients with acute myocardial infarction, severe / unstable angina pectoris or coronary artery bypass grafting within 6 months before admission; Or a history of arterial thrombosis or deep venous thrombosis;
- •There are concomitant diseases (such as severe hypertension, diabetes, thyroid disease, active infection, etc.) that seriously endanger the safety of patients or affect the completion of the study, or any laboratory abnormalities that are not suitable for participating in the clinical trial according to the judgment of the researcher,
- •Serious psychological or mental disorders that may affect the compliance study;
- •Participating in other drug clinical trials within 4 weeks before recruited.
研究组 & 干预措施
First-line treatment
Experimental
First-line treatment: Fruquintinib Combined With mFOLFOX6/FOLFIRI for eight cycles.
Maintenance treatment: Fruquintinib and Capecitabine
干预措施: Fruquintinib Combined With mFOLFOX6/FOLFIRI (Drug)
结局指标
主要结局
objective response rate (ORR)
时间窗: 36 months
Defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1.
次要结局
- disease control rate (DCR)(36 months)
- adverse events (AE)(36 months)
- Progression-Free Survival (PFS)(36 months)
- overall survival (OS)(36 months)
研究者
Zhou Fuxiang
Professor
Zhongnan Hospital
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRCColorectal CancerNCT06010888Fudan University92
尚未招募
2 期
Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARCRectal CancerNCT05575635Henan Provincial People's Hospital40
招募中
不适用
Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI TherapyRenal Cell Carcinoma, Clear Cell, SomaticNCT06317298Peking University First Hospital36
进行中（未招募）
2 期
Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell CarcinomaNon-clear Renal Cell CarcinomaNon-clear Cell Renal Cell CarcinomaNCT05831891RenJi Hospital40
招募中
2 期
The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05555901Fudan University116